Pioneering a Chemotherapy-Free Future: The ASPIRE Study and the Evolution of Advanced Breast Cancer Care
Executive Overview In the rapidly evolving landscape of modern oncology, the quest to balance therapeutic efficacy with patient quality of...
Archive
Tag: trial protocols
Akeso Doses First Patient in Landmark Phase II Trial Evaluating Novel AK146D1 and Ivonescimab Combination for Advanced Breast Cancer
Executive Overview In a significant milestone for next-generation oncology drug development, biopharmaceutical innovator Akeso has announced the successful dosing of...
Neurocrine begins Phase I trial of NBIP-‘1968 triple agonist for obesity
Executive Overview In a significant milestone for metabolic therapeutics, biopharmaceutical innovator Neurocrine Biosciences has officially commenced a Phase I clinical...
China’s Ascendance as a Global Oncology Clinical Trials Epicenter: Navigating the 30-Day IND Pathway and "China Readiness"
Executive Overview Over the past decade, the global landscape of oncology clinical research has undergone a seismic shift, with the...
Summit Therapeutics Expands Global Oncology Footprint with Phase II/III HARMONi-GU1 Trial of Ivonescimab in Advanced Urothelial Carcinoma
Executive Overview In a significant strategic expansion of its oncology clinical development pipeline, Summit Therapeutics has announced the initiation of...
Advancing Immunotherapy Frontiers: Dispatch Bio Doses First Patient in Phase I Trial of DISP-10 for Advanced Gastrointestinal Cancers
Executive Overview In a significant milestone for modern oncology and the evolution of cell-based immunotherapies, clinical-stage biopharmaceutical company Dispatch Bio...
BioVie’s Stock Plummets 33% Following SUNRISE-PD Phase IIb Trial Data Release Utilizing Novel, Company-Created EPNIC-15 Endpoint
Executive Overview In the high-stakes world of biopharmaceutical research, the line separating scientific innovation from investor skepticism is razor-thin. On...
Strategic Pivot in Oncology: Context Therapeutics Axes CT-95 Program to Preserve Cash and Double Down on Pipeline Assets CTIM-76 and CT-202
Executive Overview In a decisive move emblematic of the hyper-selective, risk-averse climate currently dominating the biotech sector, Philadelphia-based Context Therapeutics...
China’s Ascendancy in Global Clinical Trials: Inside the 2026 OCT and CTS China Conference
Executive Overview The global clinical trials landscape is undergoing a structural realignment, with the People’s Republic of China firmly anchoring...
PepGen Advances PGN-EDODM1 to Maximum Planned Dose in Phase II FREEDOM2-DM1 Trial Following Favorable Safety Review
Executive Overview In a major development for the clinical advancement of genetic medicines targeting rare muscle disorders, biotechnology innovator PepGen...
MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data
Executive Overview In a significant development for the global oncology landscape, pharmaceutical giants MSD (known as Merck & Co. in...
Moderna Doses First Participants in Phase I Trial of mRNA-1469: A Breakthrough Pursuit for a Bundibugyo Ebola Vaccine
Executive Overview In a monumental step forward for global health security, biotechnology pioneer Moderna has officially dosed its first participants...
